Total trials
54
Active
1
Phase 3
14
Total enrollment
22,974
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| PLENVU® | — | — | — | — | — | 1 | |
| Sodium picosulfate | — | — | — | — | — | 1 |
Next readouts
- 2027-01-06
Top conditions
- Colorectal Cancer6
- Colonoscopy6
- Fecal Incontinence6
- Hepatic Cirrhosis5
- Chronic Constipation4
- Colon Cancer4
- Colon Cleansing4
- Colorectal Carcinoma3
Frequently asked questions about Norgine
- How many clinical trials does Norgine have on ClinicalTrials.gov?
- Norgine is listed as the lead sponsor on 54 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Norgine's trials are in Phase 3?
- 14 of Norgine's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Norgine focus on?
- Norgine's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Colonoscopy, Fecal Incontinence, Hepatic Cirrhosis, Chronic Constipation.
- When are Norgine's next clinical trial readouts?
- Norgine has 1 upcoming primary-completion readout tracked here; the soonest is “A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy”, expected around 2027-01-06.